Document Detail


Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.
MedLine Citation:
PMID:  17155895     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Abarelix, a gonadotropin-releasing hormone antagonist, with its indication for advanced symptomatic prostate cancer, represents the newest category of hormonal therapy introduced in the past 15 years. Results from Phase II and III clinical trials demonstrate the advantages of abarelix over commonly used luteinizing hormone-releasing hormone (LHRH) agonist therapy: abarelix does not cause a surge in serum testosterone that can precipitate a flare phenomenon or worsening of disease, particularly dangerous for patients with metastatic, symptomatic disease, and produces medical castration more quickly. Abarelix was also demonstrated to promptly and substantially reduce follicle-stimulating hormone levels to lower than LHRH agonist. Study results demonstrate effective anticancer responses during extended exposure to abarelix: improvements in pain score and/or analgesic use, improvements in urinary symptoms (including urinary catheter removal) and complete avoidance of bilateral orchiectomy for patients undergoing at least 12 weeks of treatment. In Phase III clinical trials, abarelix demonstrated a similar overall safety profile when compared with LHRH agonist monotherapy, and a superior safety profile when compared with LHRH agonist plus antiandrogen combination therapy. Abarelix patients experienced a greater incidence of immediate-onset systemic allergic reactions as compared with control arms.
Authors:
Frans Debruyne; Gajanan Bhat; Marc B Garnick
Related Documents :
19404865 - Erectile dysfunction after prostatectomy: an evaluation of the risk factors.
12073225 - Temporary urethral stenting after high-energy transurethral microwave thermotherapy of ...
7542155 - Neodymium:yag laser ablation of the prostate gland--acute perioperative morbidity and s...
20711215 - The biochemical efficacy of primary cryoablation combined with prolonged total androgen...
24460505 - Catheter ablation for ventricular tachycardia in ischaemic heart disease; acute success...
6689385 - Oral and pharyngeal cancer: combined approach for multimodal therapy.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Future oncology (London, England)     Volume:  2     ISSN:  1479-6694     ISO Abbreviation:  Future Oncol     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-12-12     Completed Date:  2007-02-21     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  101256629     Medline TA:  Future Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  677-96     Citation Subset:  IM    
Affiliation:
University of Nimejian, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Hormonal / therapeutic use*
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Drug Toxicity
Gonadotropin-Releasing Hormone / antagonists & inhibitors*
Humans
Male
Oligopeptides / pharmacokinetics,  pharmacology,  therapeutic use*
Prostatic Neoplasms / drug therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Oligopeptides; 33515-09-2/Gonadotropin-Releasing Hormone; W486SJ5824/abarelix

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Next Document:  Chemoprevention of colorectal cancer: two steps forward, one step back?